期刊
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
卷 18, 期 6, 页码 1914-1921出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1055-9965.EPI-08-0980
关键词
-
资金
- National Cancer Institute [R01 CA120206-01, R42 CA121506-02]
- National Cancer Institute Early Research Detection Network [UO1 CA084951-06]
- Hepatitis B Foundation
- NATIONAL CANCER INSTITUTE [U01CA084951, R41CA121506, R01CA120206, R42CA121506] Funding Source: NIH RePORTER
Changes in glycosylation, most notably fucosylation, have been associated with the development of hepatocellular carcinoma (HCC). In this report, the levels of fucosylated kininogen (Fc-Kin) and fucosylated alpha-1antitrypsin were analyzed individually and in combination with the currently used marker, alpha-fetoprotein, and a previously identified biomarker, Golgi protein 73 (GP73), for the ability to distinguish between a diagnosis of cirrhosis and HCC. This analysis was done on serum from 113 patients with cirrhosis and 164 serum samples from patients with cirrhosis plus HCC. The levels of Fc-Kin and fucosylated alpha-1-antitrypsin were significantly higher in patients with HCC compared with those with cirrhosis (P < 0,0001). Greatest performance was achieved through the combination of Fc-Kin, alpha-fetoprotein, and GP73, giving an optimal sensitivity of 95%, a specificity of 70%, and an area under the receiver operating characteristic of 0.94. In conclusion, the altered glycosylation of serum glycoproteins can act as potential biomarkers of primary HCC when used independently or in combination with other markers of HCC. (Cancer Epidemiol Biomarkers Prev 2009;18(6):1914-21)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据